

present to the committee commercial information regarding various medical devices used in obstetrics and gynecology that are currently being evaluated by FDA.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C app. 2).

Dated: June 12, 1997.

**Michael A. Friedman,**

*Deputy Commissioner for Operations.*

[FR Doc. 97-16125 Filed 6-18-97; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Nonprescription Drugs Advisory Committee.

*General Function of the Committee:*

To provide advice and recommendations to the agency on FDA regulatory issues.

*Date and Time:* The meeting will be held on July 14, 1997, 8:30 a.m. to 5 p.m.

*Location:* Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

*Contact Person:* Andrea G. Neal or Angie Whitacre, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12541. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* The committee will hear presentations and discuss the proposed labeling requirements for over-the-counter (OTC) drug products that will enable consumers to better read and understand OTC drug product labeling and to apply this information to the safe and effective use of OTC drug products. Elsewhere in this issue of the **Federal Register**, FDA is also extending the

comment period on a proposed rule regarding labeling requirements for OTC drug products that appeared in the **Federal Register** of February 27, 1997 (62 FR 9024).

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by July 3, 1997. Oral presentations from the public will be scheduled between approximately 1:15 p.m. to 2:15 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before July 3, 1997, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: June 12, 1997.

**Michael A. Friedman,**

*Deputy Commissioner for Operations.*

[FR Doc. 97-16067 Filed 6-18-97; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Agency Information Collection Activities: Proposed Collection: Comment Request

In compliance with the requirement for opportunity for public comment on proposed data collection projects (section 3506(c)(2)(A) of Title 44, United States Code, as amended by the Paperwork Reduction Act of 1995, Public Law 104-13), the Health Resources and Services Administration (HRSA) will publish periodic summaries of proposed projects being developed for submission to OMB under the Paperwork Reduction Act of 1995. To request more information on the proposed project or to obtain a copy of the data collection plans, call the HRSA Reports Clearance Officer on (301) 443-1129.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance

of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

#### Proposed Project: Grantee Reporting Requirements for the Rural Telemedicine Grant Program

New—The Rural Telemedicine Grant Program is authorized by Section 330A of the Public Health Service Act as amended by the Health Centers Consolidation Act of 1996 (Public Law 104-229). The goal of the program is to improve access to quality health services for rural residents and reduce the isolation of rural practitioners through the use of telemedicine technologies. The two objectives of the Rural Telemedicine Grant Program are: 1) to demonstrate how telemedicine can be used as a tool in developing integrated systems of health care, which would improve access to health services for rural individuals across the lifespan and reduce the isolation of rural health care practitioners; and 2) to evaluate the feasibility, costs, appropriateness and acceptability of rural telemedicine services and technologies. Such evaluation is needed to determine how best to organize and provide telemedicine services in a sustainable manner.

Grantees will be responsible for submitting the data collection instruments listed in the burden table below. Grantees will gather information from sources involved with their telemedicine program, including patients, providers, health administrators and site coordinators. Information gathered on the data collection instruments will be entered into a database which will communicate with a central server storing all of the data from the grantee sites. Standardized data collection across all grantee sites is essential to drawing meaningful conclusions about the progress and direction of telemedicine.

The estimated burden is as follows:

Name of instrument	Type of respondent	Est. number of respondents per year	Instruments completed per respondent	Time burden per instrument (minutes)	Total burden per instrument (hours)
Patient Demographics .....	Patient .....	4,780	1	3	239
Patient Post Session .....	Patient .....	4,780	1	7	558
Provider Demographics .....	All providers (filled out once) .....	2,390	1	2	80
Consult Initiator Information .....	Provider who requested TM consult .....	1,195	4	4	319
Consult Initiator Satisfaction .....	Provider who requested TM consult .....	1,195	4	4	319
Provider Post Session .....	Consulting provider .....	1,195	4	4	319
Consult Recipient Satisfaction .....	Consulting provider .....	1,195	4	5	398
Session Information (Consulting Site) .....	Site coordinator (consulting site) .....	20	240	6	480
Session Information (Primary Care Site) ..	Site coordinator (primary care site) .....	300	16	2	160
Emergency/Triage Encounter (Consulting Site).	Emergency room staff person .....	15	10	4	10
Emergency/Triage Encounter (Originating Site).	Emergency room staff person .....	15	10	4	10
Provider Satisfaction (Periodic) .....	All providers (filled out every 4 months) ..	2,390	3	3	359
System information .....	Program administrator/technical staff .....	320	2	25	267
Program Costs .....	Program administrator .....	320	1	25	133
Total .....	.....	8,160	.....	.....	3651

Send comments to Patricia Royston, HRSA Reports Clearance Officer, Room 14-36, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received within 60 days of this notice.

Dated: June 16, 1997.

**James J. Corrigan,**

*Acting Associate Administrator for Management and Program Support.*

[FR Doc. 97-16128 Filed 6-18-97; 8:45 am]

BILLING CODE 4160-15-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Cancer Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meeting:

*Name of SEP:* A RCT of Plant-Based Diet in Breast Cancer Recurrence.

*Date:* July 14, 1997.

*Time:* 2:00 p.m.

*Place:* Teleconference, National Cancer Institute, Division of Extramural Activities, Grants Review Branch, 6130 Executive Boulevard, EPN-Room 635, Bethesda, MD 20892.

*Contact Person:* Maureen Johnson, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 635F 6130 Executive Boulevard, MSC 7410, Bethesda, MD 20892-7410, Telephone: 301/496-7565.

*Purpose/Agenda:* To evaluate and review grant application.

The meeting will be closed in accordance with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: June 13, 1997.

**LaVerne Y. Stringfield,**

*Committee Management Officer, NIH.*

[FR Doc. 97-16016 Filed 6-18-97; 8:45 am]

BILLING CODE 4140-01-M

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Cancer Institute; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meetings:

*Name of SEP:* Career Development and Mentored Peer Review.

*Date:* July 25, 1997.

*Time:* 8:30 a.m. to 5:00 p.m.

*Place:* Executive Plaza North, Conference Room E, 6130 Executive Boulevard, Rockville, MD 20852.

*Contact Person:* Wilma Woods, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North,

Room 622, 6130 Executive Boulevard, MSC 7410, Bethesda, MD 20892-7410, Telephone: 301/496-7903.

*Purpose/Agenda:* To evaluate and review grant applications.

*Name of SEP:* Polyvalent Vaccine: Phase III Trial in Phase IV Melanoma.

*Date:* August 5, 1997.

*Time:* 10:30 a.m.-Adjournment.

*Place:* Holiday Inn-Bethesda, 8120 Wisconsin Avenue, Bethesda, Maryland 20817.

*Contact Person:* Harvey P. Stein, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 611B, 6130 Executive Boulevard, MSC 7410, Bethesda, MD 20892-7410, Telephone: 301/496-7481.

*Purpose/Agenda:* To evaluate and review a grant application.

These meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: June 13, 1997.

**LaVerne Y. Stringfield,**

*Committee Management Officer, NIH.*

[FR Doc. 97-16018 Filed 6-18-97; 8:45 am]

BILLING CODE 4140-01-M